Emerging Concepts in Mesothelioma
A special issue of Cancers (ISSN 2072-6694). This special issue belongs to the section "Clinical Research of Cancer".
Deadline for manuscript submissions: 31 December 2025 | Viewed by 201
Special Issue Editors
Interests: biology of lung cancer and mesothelioma; interstitial lung diseases
Special Issue Information
Dear Colleagues,
Despite extensive research efforts, mesothelioma is still tremendously difficult to treat and mesothelioma incidence rates have not declined significantly despite asbestos bans in more developed countries, while a new incipient and protracted epidemic caused by alternate needle-shaped materials is likely. In these dreadful times, the molecular landscape, the potential treatment strategies, and hopes for the future for patients with mesothelioma are vague. We are pleased to invite you to contribute a piece of certainty to the volatile scenery of mesothelioma diagnosis and treatment in a Special Issued entitled “Emerging Concepts in Mesothelioma”, based on your excellent contributions and involvement in the field.
This Special Issue aims to summarize past understanding and recent progress in mesothelioma research and treatment, and to provide a platform for the guidance of future developments, i.e., molecular profiling, drug screening, patient subgroups and geno/phenotypes, trial design, personalized medicine, etc.
Original research, reviews, and opinion pieces are sought and the involvement of your collaborators and students is welcome. We propose a topic based on your achievements, but this is subject to change. We look forward to receiving your contributions.
Dr. Georgios T. Stathopoulos
Dr. Tonia Adamides
Guest Editors
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- mesothelioma
- asbestos
- pleura
- tumor suppressor
- cell lines
- patient-derived xenograft
- surgery
- chemotherapy
- folate antagonist
- immunotherapy
Benefits of Publishing in a Special Issue
- Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
- Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
- Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
- External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
- e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.
Further information on MDPI's Special Issue policies can be found here.
